Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our Goals: Playing Matchmaker

Read more..

For individuals with diabetes, the body’s inability to properly control blood sugar levels can lead to a wide range of other problems as time passes. One major issue is a diabetic foot ulcer (DFU), an open sore or wound that is commonly located on the bottom of the foot and caused by poor blood circulation … Continue reading Stem cell therapy for diabetic foot ulcers shows promise in new study

Read more..

In June of last year we wrote about how Dr. Scott Kitchen and his team at UCLA are engineering blood forming stem cells in order to fight HIV, a potentially deadly virus that attacks the immune system and can worsen into AIDS if left untreated. HIV causes havoc in the body by attacking T cells, … Continue reading CIRM funding helps improve immune cell therapy to combat HIV

Read more..

Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our Goals: Let’s start at the beginning shall we

Read more..

Last year we wrote about how researchers at the University of Vermont and Tufts University were able to create what they call xenobots – the world’s first living, self healing robots created from frog stem cells. Now, the same team has created an upgraded version of these robots that they have dubbed Xenobots 2.0. These … Continue reading Meet xenobots 2.0 – the next generation of living robots

Read more..

The University of California, San Francisco (UCSF), in collaboration with UC Berkeley (UCB) and UC Los Angeles (UCLA), have been given permission by the US Food and Drug Administration (FDA) to launch a first-in-human clinical trial using CRISPR technology as a gene-editing technique to cure Sickle Cell Disease. This research has been funded by CIRM … Continue reading Three UC’s Join Forces to Launch CRISPR Clinical Trial Targeting Sickle Cell Disease

Read more..

Rocket Pharmaceuticals, a company that specializes in developing genetic therapies for rare childhood disorders, just got a big boost from the European Medicines Agency (EMA). They were given a Priority Medicines (PRIME) designation for their therapy for Leukocyte Adhesion Deficiency-1 (LAD-1). CIRM is funding ($6.56 million) Rocket’s clinical trial for LAD-I, an immune disorder that … Continue reading Prime Time for Rocket

Read more..

During the global pandemic, many researchers have responded to the needs of patients severely afflicted with COVID-19 by repurposing existing therapies being developed to treat patients.  CIRM responded immediately to the pandemic and to researchers wanting to help by providing $5 million in emergency funding for COVID-19 related projects.  One of these grants ($349,999), awarded to Dr. … Continue reading CIRM funding helps identify potential COVID-19 treatment

Read more..

Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our Goals: Scoring a half century

Read more..

3D printing technology has revolutionized the way we think about creating things with complex designs with the simple click of a button. The ability to be able to give a computer a specific set of instructions and hit “print” is appealing in this modern era of instant gratification and convenience. In the regenerative medicine field, … Continue reading Newly designed “bioink” get us one step closer to 3D printed organs

Read more..